During the past decade, Great Lakes Gastroenterology Research, LLC conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 24 clinical trials were completed, i.e. on average, 40.7% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 21 clinical trials were completed. i.e. 91.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Great Lakes Gastroenterology Research, LLC" #1 sponsor was "Pfizer" with 9 trials, followed by "Exact Sciences Corporation" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Celgene" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Great Lakes Gastroenterology Research, LLC" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 4 trials as a collaborator, "Gilead Sciences" with 4 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Allergan Sales, LLC" with 1 trials as a collaborator and "Bernstein Clinical Research Center" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Great Lakes Gastroenterology Research, LLC" are "Ulcerative Colitis" (13 trials), "Crohn Disease" (8 trials), "Colorectal Cancer" (6 trials), "Crohn's Disease" (5 trials) and "Eosinophilic Esophagitis" (3 trials). Many other conditions were trialed in "Great Lakes Gastroenterology Research, LLC" in a lesser frequency.

Most popular intervention types in "Great Lakes Gastroenterology Research, LLC" are "Drug" (39 trials), "Other" (9 trials), "Device" (7 trials), "Biological" (6 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Etrasimod" (6 trials), "Filgotinib" (5 trials), "Etrolizumab" (4 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "Great Lakes Gastroenterology Research, LLC" are 61 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Great Lakes Gastroenterology Research, LLC". undefined are not yet recruiting, 14 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in Great Lakes Gastroenterology Research, LLC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Great Lakes Gastroenterology Research, LLC, 0 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".